{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T07:08:48Z","timestamp":1775027328164,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001266","name":"Action Duchenne","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001266","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Normative data are necessary for validation of new outcome measures. Recently, the 95th centile of stride speed was qualified by the European Medicines Agency as a valid secondary outcome for clinical trials in subjects with Duchenne muscular dystrophy. This study aims to obtain normative data on spontaneous stride velocity and length in a non-controlled environment and their evolution after 12\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>Ninety-one healthy volunteers (50 females, 41 males), with a mean age of 16\u00a0years and 2\u00a0months, were recruited and assessed at baseline and 12\u00a0months later. The 4-stair climb, 6-min walk test, 10-m walk test and rise from floor assessments were performed. Stride length, stride velocity, and the distance walked per hour were studied in an everyday setting for one month after each evaluation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 91 subjects assessed, 82 provided more than 50\u00a0h of recordings at baseline; and 73 subjects provided the same at the end of the year. We observed significant positive correlations of the stride length with age and height of participants, and a significant increase of the median stride length in children after the period. In this group, the 95th centile stride velocity was not correlated with age and was stable after one year. All measures but the 10MWT were stable in adults after a one-year period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study provides with data on the influence of age, height, and gender on stride velocity and length as well as accounting for natural changes after one year in controls.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-021-01956-5","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T07:03:01Z","timestamp":1626678181000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Normative data on spontaneous stride velocity, stride length, and walking activity in a non-controlled environment"],"prefix":"10.1186","volume":"16","author":[{"given":"Margaux","family":"Poleur","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ulinici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aurore","family":"Daron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian Dal","family":"Farra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Demonceau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M\u00e9lanie","family":"Annoussamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vissi\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damien","family":"Eggenspieler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-4061","authenticated-orcid":false,"given":"Laurent","family":"Servais","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"issue":"1","key":"1956_CR1","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","volume":"12","author":"S Ryder","year":"2017","unstructured":"Ryder S, Leadley RM, Armstrong N, Westwood M, de Kock S, Butt T, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. Orphanet J Rare Dis. 2017;12(1):79. https:\/\/doi.org\/10.1186\/s13023-017-0631-3.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1956_CR2","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","volume":"24","author":"JK Mah","year":"2014","unstructured":"Mah JK, Korngut L, Dykeman J, Day L, Pringsheim T, Jette N. A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy. Neuromuscul Disord. 2014;24(6):482\u201391. https:\/\/doi.org\/10.1016\/j.nmd.2014.03.008.","journal-title":"Neuromuscul Disord"},{"issue":"8","key":"1956_CR3","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1001\/jamaneurol.2020.1264","volume":"77","author":"PR Clemens","year":"2020","unstructured":"Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, et al. Safety, tolerability, and efficacy of viltolarsen in boys with duchenne muscular dystrophy amenable to exon 53 skipping: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77(8):982\u201391. https:\/\/doi.org\/10.1001\/jamaneurol.2020.1264.","journal-title":"JAMA Neurol"},{"issue":"21","key":"1956_CR4","doi-asserted-by":"publisher","first-page":"e2270","DOI":"10.1212\/wnl.0000000000009233","volume":"94","author":"DE Frank","year":"2020","unstructured":"Frank DE, Schnell FJ, Akana C, El-Husayni SH, Desjardins CA, Morgan J, et al. Increased dystrophin production with golodirsen in patients with Duchenne muscular dystrophy. Neurology. 2020;94(21):e2270\u201382. https:\/\/doi.org\/10.1212\/wnl.0000000000009233.","journal-title":"Neurology"},{"issue":"10101","key":"1956_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/s0140-6736(17)31611-2","volume":"390","author":"CM McDonald","year":"2017","unstructured":"McDonald CM, Campbell C, Torricelli RE, Finkel RS, Flanigan KM, Goemans N, et al. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390(10101):1489\u201398. https:\/\/doi.org\/10.1016\/s0140-6736(17)31611-2.","journal-title":"Lancet"},{"issue":"5","key":"1956_CR6","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/ana.23982","volume":"74","author":"JR Mendell","year":"2013","unstructured":"Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP, et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Ann Neurol. 2013;74(5):637\u201347. https:\/\/doi.org\/10.1002\/ana.23982.","journal-title":"Ann Neurol"},{"issue":"4","key":"1956_CR7","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/mus.24332","volume":"50","author":"K Bushby","year":"2014","unstructured":"Bushby K, Finkel R, Wong B, Barohn R, Campbell C, Comi GP, et al. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle Nerve. 2014;50(4):477\u201387. https:\/\/doi.org\/10.1002\/mus.24332.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1956_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.nmd.2017.10.004","volume":"28","author":"N Goemans","year":"2018","unstructured":"Goemans N, Mercuri E, Belousova E, Komaki H, Dubrovsky A, McDonald CM, et al. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen Duchenne muscular dystrophy. Neuromuscul Disord. 2018;28(1):4\u201315. https:\/\/doi.org\/10.1016\/j.nmd.2017.10.004.","journal-title":"Neuromuscul Disord"},{"issue":"10","key":"1956_CR9","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/s1474-4422(14)70195-4","volume":"13","author":"T Voit","year":"2014","unstructured":"Voit T, Topaloglu H, Straub V, Muntoni F, Deconinck N, Campion G, et al. Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study. Lancet Neurol. 2014;13(10):987\u201396. https:\/\/doi.org\/10.1016\/s1474-4422(14)70195-4.","journal-title":"Lancet Neurol"},{"key":"1956_CR10","unstructured":"Assessment report for Kyndrisa. European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-kyndrisa_en.pdf. Accessed 1 Dec 2020."},{"issue":"2","key":"1956_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001953","volume":"13","author":"L Piwek","year":"2016","unstructured":"Piwek L, Ellis DA, Andrews S, Joinson A. The Rise of Consumer Health Wearables: Promises and Barriers. PLoS Med. 2016;13(2): e1001953. https:\/\/doi.org\/10.1371\/journal.pmed.1001953.","journal-title":"PLoS Med"},{"issue":"6","key":"1956_CR12","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1097\/wco.0000000000000026","volume":"26","author":"BH Dobkin","year":"2013","unstructured":"Dobkin BH. Wearable motion sensors to continuously measure real-world physical activities. Curr Opin Neurol. 2013;26(6):602\u20138. https:\/\/doi.org\/10.1097\/wco.0000000000000026.","journal-title":"Curr Opin Neurol"},{"key":"1956_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41746-019-0082-4","volume":"2","author":"B Caulfield","year":"2019","unstructured":"Caulfield B, Reginatto B, Slevin P. Not all sensors are created equal: a framework for evaluating human performance measurement technologies. NPJ Digit Med. 2019;2:7. https:\/\/doi.org\/10.1038\/s41746-019-0082-4.","journal-title":"NPJ Digit Med"},{"issue":"6","key":"1956_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156696","volume":"11","author":"AG Le Moing","year":"2016","unstructured":"Le Moing AG, Seferian AM, Moraux A, Annoussamy M, Dorveaux E, Gasnier E, et al. A movement monitor based on magneto-inertial sensors for non-ambulant patients with duchenne muscular dystrophy: a pilot study in controlled environment. PLoS ONE. 2016;11(6): e0156696. https:\/\/doi.org\/10.1371\/journal.pone.0156696.","journal-title":"PLoS ONE"},{"key":"1956_CR15","doi-asserted-by":"publisher","DOI":"10.3791\/59668","author":"C Lilien","year":"2019","unstructured":"Lilien C, Gasnier E, Gidaro T, Seferian A, Grelet M, Vissi\u00e8re D, et al. Home-based monitor for gait and activity analysis. J Vis Exp. 2019. https:\/\/doi.org\/10.3791\/59668.","journal-title":"J Vis Exp"},{"key":"1956_CR16","unstructured":"Qualification opinion on stride velocity 95th centile as a secondary endpoint in Duchenne muscular dystrophy measured by a valid and suitable wearable device*European Medicines Agency. \nhttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/qualification-opinion-stride-velocity-95th-centile-secondary-endpoint-duchenne-muscular-dystrophy_en.pdf. Accessed 15 July 2021."},{"issue":"7","key":"1956_CR17","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.nmd.2019.06.003","volume":"29","author":"M Haberkamp","year":"2019","unstructured":"Haberkamp M, Moseley J, Athanasiou D, de Andres-Trelles F, Elferink A, Rosa MM, et al. European regulators\u2019 views on a wearable-derived performance measurement of ambulation for Duchenne muscular dystrophy regulatory trials. Neuromuscul Disord. 2019;29(7):514\u20136. https:\/\/doi.org\/10.1016\/j.nmd.2019.06.003.","journal-title":"Neuromuscul Disord"},{"issue":"7","key":"1956_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201004","volume":"13","author":"A Chabanon","year":"2018","unstructured":"Chabanon A, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Prospective and longitudinal natural history study of patients with Type 2 and 3 spinal muscular atrophy: baseline data NatHis-SMA study. PLoS ONE. 2018;13(7): e0201004. https:\/\/doi.org\/10.1371\/journal.pone.0201004.","journal-title":"PLoS ONE"},{"key":"1956_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51281","author":"M Annoussamy","year":"2020","unstructured":"Annoussamy M, Seferian AM, Daron A, P\u00e9r\u00e9on Y, Cances C, Vuillerot C, et al. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann Clin Transl Neurol. 2020. https:\/\/doi.org\/10.1002\/acn3.51281.","journal-title":"Ann Clin Transl Neurol"},{"issue":"12","key":"1956_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084120","volume":"8","author":"N Goemans","year":"2013","unstructured":"Goemans N, Klingels K, van den Hauwe M, Boons S, Verstraete L, Peeters C, et al. Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years. PLoS ONE. 2013;8(12): e84120. https:\/\/doi.org\/10.1371\/journal.pone.0084120.","journal-title":"PLoS ONE"},{"issue":"7","key":"1956_CR21","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1007\/s00415-020-09800-9","volume":"267","author":"JY Hogrel","year":"2020","unstructured":"Hogrel JY, Decostre V, Ledoux I, de Antonio M, Niks EH, de Groot I, et al. Normalized grip strength is a sensitive outcome measure through all stages of Duchenne muscular dystrophy. J Neurol. 2020;267(7):2022\u20138. https:\/\/doi.org\/10.1007\/s00415-020-09800-9.","journal-title":"J Neurol"},{"issue":"4","key":"1956_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121799","volume":"10","author":"AM Seferian","year":"2015","unstructured":"Seferian AM, Moraux A, Canal A, Decostre V, Diebate O, Le Moing AG, et al. Upper limb evaluation and one-year follow up of non-ambulant patients with spinal muscular atrophy: an observational multicenter trial. PLoS ONE. 2015;10(4): e0121799. https:\/\/doi.org\/10.1371\/journal.pone.0121799.","journal-title":"PLoS ONE"},{"issue":"4","key":"1956_CR23","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/mus.21544","volume":"41","author":"CM McDonald","year":"2010","unstructured":"McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve. 2010;41(4):500\u201310. https:\/\/doi.org\/10.1002\/mus.21544.","journal-title":"Muscle Nerve"},{"issue":"1","key":"1956_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000486347","volume":"2","author":"B Perry","year":"2018","unstructured":"Perry B, Herrington W, Goldsack JC, Grandinetti CA, Vasisht KP, Landray MJ, et al. Use of mobile devices to measure outcomes in clinical research, 2010\u20132016: a systematic literature review. Digit Biomark. 2018;2(1):11\u201330. https:\/\/doi.org\/10.1159\/000486347.","journal-title":"Digit Biomark"},{"issue":"1","key":"1956_CR25","doi-asserted-by":"publisher","DOI":"10.1098\/rsos.170818","volume":"5","author":"X Fang","year":"2018","unstructured":"Fang X, Liu C, Jiang Z. Reference values of gait using APDM movement monitoring inertial sensor system. R Soc Open Sci. 2018;5(1): 170818. https:\/\/doi.org\/10.1098\/rsos.170818.","journal-title":"R Soc Open Sci"},{"key":"1956_CR26","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.gaitpost.2020.05.010","volume":"80","author":"S Voss","year":"2020","unstructured":"Voss S, Joyce J, Biskis A, Parulekar M, Armijo N, Zampieri C, et al. Normative database of spatiotemporal gait parameters using inertial sensors in typically developing children and young adults. Gait Posture. 2020;80:206\u201313. https:\/\/doi.org\/10.1016\/j.gaitpost.2020.05.010.","journal-title":"Gait Posture"},{"issue":"4","key":"1956_CR27","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1007\/s00415-020-09696-5","volume":"267","author":"VV Shah","year":"2020","unstructured":"Shah VV, McNames J, Mancini M, Carlson-Kuhta P, Spain RI, Nutt JG, et al. Quantity and quality of gait and turning in people with multiple sclerosis, Parkinson\u2019s disease and matched controls during daily living. J Neurol. 2020;267(4):1188\u201396. https:\/\/doi.org\/10.1007\/s00415-020-09696-5.","journal-title":"J Neurol"},{"key":"1956_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2020.574443","volume":"8","author":"I Wiedmann","year":"2020","unstructured":"Wiedmann I, Grassi M, Duran I, Lavrador R, Alberg E, Daumer M, et al. Accelerometric Gait analysis devices in children-will they accept them? results from the AVAPed study. Front Pediatr. 2020;8: 574443. https:\/\/doi.org\/10.3389\/fped.2020.574443.","journal-title":"Front Pediatr"},{"issue":"1","key":"1956_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.gaitpost.2006.06.003","volume":"25","author":"SC Dusing","year":"2007","unstructured":"Dusing SC, Thorpe DE. A normative sample of temporal and spatial gait parameters in children using the GAITRite electronic walkway. Gait Posture. 2007;25(1):135\u20139. https:\/\/doi.org\/10.1016\/j.gaitpost.2006.06.003.","journal-title":"Gait Posture"},{"issue":"3","key":"1956_CR30","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/s0966-6362(01)00097-2","volume":"13","author":"MR Pierrynowski","year":"2001","unstructured":"Pierrynowski MR, Galea V. Enhancing the ability of gait analyses to differentiate between groups: scaling gait data to body size. Gait Posture. 2001;13(3):193\u2013201. https:\/\/doi.org\/10.1016\/s0966-6362(01)00097-2.","journal-title":"Gait Posture"},{"key":"1956_CR31","unstructured":"Clinical Review Report: Nusinersen (Spinraza): (Biogen Canada Inc.): Indication: Treatment of patients with 5q SMA [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jan. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK533989\/. Accessed 14 July 2021."},{"issue":"11","key":"1956_CR32","doi-asserted-by":"publisher","first-page":"2218","DOI":"10.1016\/j.apmr.2013.04.001","volume":"94","author":"C de Lattre","year":"2013","unstructured":"de Lattre C, Payan C, Vuillerot C, Rippert P, de Castro D, B\u00e9rard C, et al. Motor function measure: validation of a short form for young children with neuromuscular diseases. Arch Phys Med Rehabil. 2013;94(11):2218\u201326. https:\/\/doi.org\/10.1016\/j.apmr.2013.04.001.","journal-title":"Arch Phys Med Rehabil"},{"key":"1956_CR33","doi-asserted-by":"publisher","first-page":"S228","DOI":"10.1016\/j.nmd.2015.06.159","volume":"25","author":"K Klingels","year":"2015","unstructured":"Klingels K, Van Verdegem L, van den Hauwe M, Buyse G, Goemans N. Reference values for the three-minute walk test, North Star ambulatory assessment and timed tests in typically developing boys aged 2.5\u20135 years. Neuromuscul Disord. 2015;25:S228. https:\/\/doi.org\/10.1016\/j.nmd.2015.06.159.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"1956_CR34","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1002\/acn3.283","volume":"3","author":"SJ Kolb","year":"2016","unstructured":"Kolb SJ, Coffey CS, Yankey JW, Krosschell K, Arnold WD, Rutkove SB, et al. Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. Ann Clin Transl Neurol. 2016;3(2):132\u201345. https:\/\/doi.org\/10.1002\/acn3.283.","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"1956_CR35","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.nmd.2012.10.022","volume":"23","author":"L Servais","year":"2013","unstructured":"Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, et al. Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients. Neuromuscul Disord. 2013;23(2):139\u201348. https:\/\/doi.org\/10.1016\/j.nmd.2012.10.022.","journal-title":"Neuromuscul Disord"},{"key":"1956_CR36","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jpeds.2016.02.067","volume":"173","author":"MM Lamb","year":"2016","unstructured":"Lamb MM, West NA, Ouyang L, Yang M, Weitzenkamp D, James K, et al. Corticosteroid treatment and growth patterns in ambulatory males with Duchenne muscular dystrophy. J Pediatr. 2016;173:207-13.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2016.02.067.","journal-title":"J Pediatr"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01956-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-021-01956-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-021-01956-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T07:13:44Z","timestamp":1626678824000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-021-01956-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1956"],"URL":"https:\/\/doi.org\/10.1186\/s13023-021-01956-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-178075\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of the Citadelle Regional Hospital Centre in Li\u00e8ge (Belgian N\u00b0: B412201731844), and the experiment was conducted in accordance with the good clinical practice and with the Declaration of Helsinki (2013). Prior to their inclusion in the study, all participants (and\/or their legal guardians) gave their full written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Academic authors declare no competing interests. Melanie Annoussamy and Damien Eggenspieler are employed by Synsav, the medium-sized enterprise responsible for ActiMyo\u00ae development. David Vissi\u00e8re is the CEO, founder and main shareholder of Sysnav.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"318"}}